Brilinta (Ticagrelor)

Brilinta, generically known as Ticagrelor, is an antiplatelet medication widely prescribed to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) or a history of heart attacks. This medication works by inhibiting platelet aggregation, thereby preventing blood clots that could lead to serious complications such as heart attacks or strokes.

Key highlights of Brilinta include:

• Mechanism of Action: Ticagrelor selectively and reversibly inhibits the P2Y12 component of ADP receptors on platelets, leading to decreased platelet activation and aggregation.


• Indications: Brilinta is primarily indicated for patients with a history of myocardial infarction and those experiencing acute coronary syndromes, including unstable angina and non-ST elevation myocardial infarction (NSTEMI).


• Dosing: The typical starting dose is 180 mg, followed by a maintenance dose of 90 mg twice daily. It is crucial for patients to adhere to the prescribed dosing regimen for optimal efficacy.


• Benefits: Clinical studies have shown that Brilinta significantly reduces the risk of cardiovascular death, heart attacks, and strokes compared to other antiplatelet therapies.


• Side Effects: Common side effects may include bleeding, shortness of breath, and headache. Patients should be monitored for any signs of unusual bleeding or severe allergic reactions.


• Drug Interactions: Brilinta can interact with certain medications, particularly those affecting cytochrome P450 enzymes. It is essential for patients to inform their healthcare providers about all medications they are taking.


• Precautions: Patients with a history of bleeding disorders, liver impairment, or those undergoing surgery should use Brilinta with caution. Regular follow-ups with healthcare providers are recommended to ensure safety.

Brilinta represents a vital option in the management of patients at risk of serious cardiovascular events, contributing to improved outcomes and enhanced quality of life.

• Ticagrelor


• Microcrystalline cellulose


• Lactose monohydrate


• Hydroxypropyl cellulose


• Magnesium stearate


• Iron oxide red


• Iron oxide yellow

Brilinta (Ticagrelor) is a medication used to reduce the risk of stroke, heart attack, and other cardiovascular complications in patients with certain heart conditions. It is important to follow the prescribed dosage and instructions from your healthcare provider.

Before taking Brilinta, inform your doctor about any other medications you are currently using, especially blood thinners, as well as any medical conditions, particularly those related to bleeding or liver issues.

Brilinta is typically taken twice daily, with or without food. It is crucial to take the medication at the same times each day to maintain an even level in your bloodstream.

1. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet, as this can affect how the medication works.


2. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once.


3. Continue taking Brilinta as directed by your healthcare provider, even if you feel well. Stopping the medication abruptly can increase your risk of serious cardiovascular events.


4. Attend all scheduled follow-up appointments with your doctor to monitor your condition and the effects of the medication.

Common side effects may include shortness of breath, headache, or dizziness. If you experience unusual bleeding, severe headache, or any allergic reactions, seek medical attention immediately.

Brilinta may interact with other medications, so always inform your healthcare provider about any other treatments you are undergoing. Keep this medication out of reach of children and store it at room temperature away from moisture and heat.